San Diego-based Ambit Biosciences, a firm discovering, developing and commercializing targeted small molecule therapeutics for treating cancer, has filed for an IPO, saying it is looking to raise up to $86.25M on the Nasdaq Global Market. The firm said it has applied to list as AMBT. The IPO is being underwritten by J.P. Morgan, Credit Suisse, Leerink Swann, and Wedbush PacGrow Life Sciences. The company is backed by Apposite Healthcare Fund, OrbiMed Investors, Forward Ventures, GrowthWorks Canada, GIMV, MediImmune, PErseus-Soros Biopharmaceuticals Fund, and Roche.
Top NewsMonday, November 8, 2010
Ambit Files For IPO